Global Eosinophilic Esophagitis Market Opportunity Assessment and Forecast Report 2021-2030: Epidemiology, Current Treatment Options, Unmet Needs and Opportunities, Pipeline Assessment, R&D Strategies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Eosinophilic Esophagitis – Opportunity Assessment and Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

Eosinophilic esophagitis (EoE) is defined as a chronic, immune-mediated, atopic inflammatory condition of the esophagus, recognized over the past two decades. In EoE, eosinophils infiltrate the esophagus, contributing to tissue damage and chronic inflammation. It is diagnosed by histologic analysis of 15 eosinophils per high power field (eos/hpf) in one or more esophageal biopsy specimens and exclusion of pathologic gastrointestinal reflux disease (GERD). EoE symptoms are similar to GERD, which is why the two conditions were thought to be the same for so long. The key to diagnosing EoE is that patients with EoE don’t improve with GERD medications.

Key Highlights

• A large number of symptomatic treatments are currently used off-label. The most frequently used drug classes are proton pump inhibitors and corticosteroids.
• The main driver to growth in the EoE market is the introduction of high-priced biologics.
• The main barrier to growth in the EoE market is low diagnosis rates caused by limited disease awareness.
• The greatest unmet needs within the EoE market are lack of data, the need for more effective or curative therapies, increased awareness and education, and more options for the pediatric population.

Key Questions Answered

• Which unmet needs are limiting the treatment of EoE in the US?
• What strategies can the pharmaceutical industry employ to increase treatment rates for EoE?
• What effect will the launch of generics have on the sales of branded agents?
• What are the main R&D trends in the EoE market and which companies are leading the way?
• Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope

• Overview of EoE including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Topline EoE market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
• Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting EoE therapeutics sales in the US.
• Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the US EoE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Topics Covered:

1 Executive Summary

1.1 Executive Summary

2 Disease Overview

2.1 Overview of Eosinophilic Esophagitis

2.2 Eosinophilic Esophagitis SWOT Analysis

3 Epidemiology

3.1 Lifetime Diagnosed Prevalent Cases of EoE, All Ages, Both Sexes, 2020-2030

3.2 Sources and Methodology for Lifetime Diagnosed Prevalent Cases of EoE

4 Current Treatment Options

4.1 Treatment Paradigm

4.2 Treatment Algorithm

4.3 Marketed Products

4.4 Product Profile: Proton Pump Inhibitors

4.5 Product Profile: Glucocorticoid Receptor Agonists

5 Unmet Needs and Opportunities

5.1 Lack of Data

5.2 More Effective or Curative Therapies

5.3 Increased Awareness and Education

5.4 Treatment Options for the Pediatric Population

6 Pipeline Assessment

6.1 Eosinophilic Esophagitis Pipeline Overview

6.2 Leading Pipeline Agents

6.3 Product Profile: Takeda Pharmaceutical’s Eohilia (budesonide)

6.4 Product Profile: Ellodi Pharmaceuticals’ APT-1011 (fluticasone propionate)

6.5 Product Profile: Bristol Myers Squibb’s Cendakimab (RPC-4046)

6.6 Product Profile: AstraZeneca’s Fasenra (benralizumab)

6.7 Product Profile: Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab)

6.8 Product Profile: Allakos’ Lirentelimab (AK-002)

7 R&D Strategies

7.1 Trends in Clinical Trial Design in Eosinophilic Esophagitis

7.2 FDA Treatment Guidance for Industry – EoE

7.3 Trends in Deal-Making in Eosinophilic Esophagitis

8 Market Outlook

8.1 Eosinophilic Esophagitis Market Forecast

8.2 Impact of COVID-19 on Eosinophilic Esophagitis

8.3 Market Drivers and Barriers

9 Appendix

Companies Mentioned

• Takeda Pharmaceuticals
• Ellodi Pharmaceuticals
• Bristol Myers Squibb
• AstraZeneca
• GlaxoSmithKline
• Regeneron Pharmaceuticals (Sanofi)
• Allakos Inc
• Arena Pharmaceuticals
• Revolo Biotherapeutics
• DBV Technologies
• Landos Biopharma

For more information about this report visit https://www.researchandmarkets.com/r/eecygj

Source: GlobalData

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900